Simmons Bank Has $1.63 Million Position in Gilead Sciences, Inc. (GILD)
Simmons Bank cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,984 shares of the biopharmaceutical company’s stock after selling 511 shares during the quarter. Simmons Bank’s holdings in Gilead Sciences were worth $1,627,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of GILD. TT International increased its stake in Gilead Sciences by 2.4% in the second quarter. TT International now owns 88,014 shares of the biopharmaceutical company’s stock worth $6,236,000 after purchasing an additional 2,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences in the second quarter worth $147,000. Cubist Systematic Strategies LLC increased its stake in Gilead Sciences by 75.1% in the second quarter. Cubist Systematic Strategies LLC now owns 10,506 shares of the biopharmaceutical company’s stock worth $744,000 after purchasing an additional 4,507 shares during the period. Maverick Capital Ltd. increased its stake in Gilead Sciences by 161.7% in the second quarter. Maverick Capital Ltd. now owns 24,760 shares of the biopharmaceutical company’s stock worth $1,753,000 after purchasing an additional 15,300 shares during the period. Finally, Monetary Management Group Inc. increased its stake in Gilead Sciences by 3.7% in the second quarter. Monetary Management Group Inc. now owns 27,145 shares of the biopharmaceutical company’s stock worth $1,921,000 after purchasing an additional 975 shares during the period. Institutional investors own 76.23% of the company’s stock.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 494,999 shares of company stock worth $37,404,139. 1.30% of the stock is owned by corporate insiders.
A number of analysts have weighed in on the company. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Thursday. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and increased their target price for the stock from $73.25 to $73.77 in a research note on Monday, November 13th. Mizuho increased their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Finally, BMO Capital Markets cut their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.11.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.22 on Monday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The firm has a market capitalization of $96,951.29, a PE ratio of 7.75, a P/E/G ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter last year, the company earned $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.69%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.